I WILL UPDATE IF I FIND MORE
$Poseida Therapeutics (PSTX.US)$ TOP PLAY. To be acquired by Roche for $1.5B for $9.00/share. “Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash”
$Citius Pharmaceuticals (CTXR.US)$  News halt after hours with PR today of...

$The Arena Group (AREN.US)$ $Greenidge Generation (GREE.US)$ $Adagio Medical (ADGM.US)$ $Innovation Beverage Group (IBG.US)$ $Fundamental Global (FGF.US)$ $Serve Robotics (SERV.US)$ $ReShape Lifesciences (RSLS.US)$ $XTI Aerospace (XTIA.US)$ $VivoPower (VVPR.US)$ $Siyata Mobile (SYTA.US)$ $Sidus Space (SIDU.US)$ $Motorsport Games (MSGM.US)$ $MediciNova (MNOV.US)$ $Banzai International (BNZI.US)$ $Safe Pro Group (SPAI.US)$ $T2 Biosystems (TTOO.US)$ $Beneficient (BENF.US)$ $eHealth (EHTH.US)$ $Trinity Biotech (TRIB.US)$
...

$FRASERS HOSPITALITY TRUST (ACV.SG)$
FRASERS Hospitality Trust  recorded DPS of S$0.011682 for the second half of its financial year ended Sep 30, -0.8%
The distribution will be paid out on Dec 27

$Sembcorp Ind (U96.SG)$
wow... kissing 5.0 soon

$LogicMark (LGMK.US)$
NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING
PERSON WITH:
7.SOLE VOTING POWER
4,074,58718.
SHARED VOTING POWER 09
SOLE DISPOSITIVE POWER
4,074,587110
SHARED DISPOSITIVE POWER0
11.Aggregate Amount Beneficially Owned by Such Reporting Person
 
4,074,5871
 
12.Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
 
13.Percent of Class Represented by Amount in Row (11)
 
67.2%1
 
14.Type of Reporting Person (See Instructions)
...

$Tevogen Bio Holdings (TVGN.US)$
Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity
• CD8 Technology Services, LLC ("CD8 Technology") to provide turn-key facility for Tevogen Bio
• Reinforces Tevogen Bio's commitment to preserving shareholder value
• Expected to further enhance Tevogen Bio's ambitious growth agenda
WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen...